Valeritas Holdings Priced, Nasdaq: VLRX

Markets a disposable device that delivers insulin therapy for Type 2 diabetes.

Industry: Health Care

Latest Trade: $5.00 0.00 (0.0%)

First Day Return: -28.8%

Return from IPO: -50.0%

Industry: Health Care

We are a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. We designed our first commercialized product, the V-Go Wearable Insulin Delivery Device, or V-Go, to help patients with Type 2 diabetes who require insulin to achieve and maintain their target blood glucose goals. V-Go is indicated for continuous subcutaneous infusion of insulin over 24 hours and on-demand bolus dosing in two-unit increments in adult patients requiring insulin. V-Go is a small, discreet and easy-to-use disposable insulin delivery device that a patient adheres to his or her skin. V-Go is not considered durable medical equipment because it is not intended for repeated use. Each V-Go device is designed to be worn for 24 hours, removed from the body and disposed. V-Go enables patients to closely mimic the body’s normal physiologic pattern of insulin delivery throughout the day and to manage their diabetes with insulin without the need to plan a daily routine around multiple daily injections.
more less
IPO News for Valeritas Holdings
more
IPO Data
IPO File Date 02/06/2017
Offer Price $10.00
Price Range $9.00 - $11.00
Offer Shares (mm) 5.3
Deal Size ($mm) $53
IPO Data
IPO Date 03/22/2017
Offer Price $10.00
Price Range $9.00 - $11.00
Offer Shares (mm) 5.3
Deal Size ($mm) $53
Underwriters
more
Company Data
Headquarters Bridgewater, NJ
Founded 2006
Employees 82
Website www.valeritas.com